Covid-19 vaccinesrare adverse eventsSARS-CoV-2vaccine efficacyvariants of concernSince the outbreak of coronavirus disease 2019 (Covid-19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of confirmed infections has risen to more than 242...
Current COVID-19 vaccines are based on the SARS-CoV-2 spike protein, which the virus uses to bind to and infect host cells, of the original Wuhan-hu-1. But the emerging “variants of concern”—deemed so because they appear to be more transmissible or deadlier than the wild-type SARS-...
It is obvious that a successful COVID-19 vaccination program is needed to end the pandemic and allow a return to normal life5,6. By the end of February 2021, two COVID-19 vaccines had been approved in the U.S.: BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna)7. In two large ...
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern (VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 vaccines mainly include inactivated, live attenuated, viral vector, protein subunit, RNA, DNA, and virus-like particle (VLP) ...
It was urgent and necessary to synthesize the evidence for vaccine effectiveness (VE) against SARS-CoV-2 variants of concern (VOC). We conducted a systematic review and meta-analysis to provide a comprehensive overview of the effectiveness profile of COV
[04:17.52]After another year of face coverings, restrictions, [04:22.48]vaccines and variants, people are beginning [04:26.48]to wonder whether this pandemic will ever go away. [04:30.80]The answer is yes and no. ...
1:24 min Are COVID-19 vaccines effective against new variants of concern of the SARS-CoV-2 virus? 4:07 min Why do immunocompromised people need an additional dose of COVID-19 vaccines? 1:05 min Why are some vaccinated people getting sick with COVID-19 and in some cases being hospitaliz...
Several coronavirus variants with the potential to be more transmissible have caused global concern over whether existing vaccines will still protect the world from a virus that is constantly mutating.
Timely evaluation of the protective effects of Coronavirus Disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern is urgently needed to inform pandemic control planning. Based on 78 vaccine efficacy or effectiveness (VE) data from ...
CoVac-1 is a multi-peptide-based vaccine candidate designed to induce, upon a single vaccination, a broad and long-lasting SARS-CoV-2 T cell immunity resembling that acquired by natural infection, which is not affected by evolving viral variants of concern (VOCs). Thus, CoVac-1 is composed...